Genzyme hopes to purchase rest of IG Laboratories:
This article was originally published in Clinica
Genzyme wishes to purchase the remaining shares of IG Laboratories, the genetic testing company in which it already has a 69% stake. It has approached IG's directors and proposed a tax-free merger under which IG stockholders would receive 0.12368 Genzyme shares for each IG share. This values IG shares at $4.76 - a premium of 29% on the share price prior to the offer - and the total transaction at $14 million.
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.